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Amplifying cancer’s signal
In the United States and most other developed countries, lung cancer is the leading cause of 
cancer-related death. Notoriously hard to detect in 
its early stages, the overall five-year survival rate for 
the disease is only 14 percent. 
Maik Hüttemann, Ph.D., assistant professor of 
molecular medicine and genetics in Wayne State 
University’s School of Medicine, along with research 
associate Jeffrey Doan, Ph.D., is working to improve 
those odds by developing a screening technique for 
a gene that may be indicative of lung cancer.  He 
is developing a platform technology which utilizes 
probe ligation and rolling circle amplification to 
screen for any target gene in many different types 
of diseases.
To begin, though, the research has centered on 
cytochrome c oxidase (or COX), the “pacemaker 
of aerobic metabolism.” The level of COX4-2, a 
lung-specific COX gene, directly correlates with 
the amount of oxygen in lung tissue. “And oxygen 
levels,” Hüttemann said, “can indicate whether 
tissue is healthy or cancerous.”
“In 70 percent of all human diseases, we find a 
change in the oxygen environment,” Hüttemann 
said. “COX4-2 levels may be one of the early 
indicators of that shift in lung cancer tissue.”
In healthy cells, the primary type of metabolism 
is aerobic oxidative phosphorylation in the 
mitochondria. This type of metabolism produces 
adenosine triphosphate (ATP), biological energy that 
fuels most of the body’s processes. In cancer cells, 
however, the predominant type of metabolism is 
glycolysis, an anaerobic process. Rather than energy, 
products of glycolysis and associated pathways are 
required for the proliferating cell. “The switch from 
aerobic to glycolytic metabolism reflects the cancer 
cell’s need for building blocks for DNA, lipid, and 
protein biosynthesis,” Hüttemann said.
 In an ongoing study, Hüttemann and colleagues 
found that COX4-2 is dramatically downregulated 
in lung cancer. This was measured against the 
somatic form of the gene, COX4-1, which is 
expressed at similar levels in cancer and non-cancer 
tissue. The finding holds for various types of lung 
cancer and lung cancer cell lines – approximately 
80 were tested – including a cell culture model 
simulating carcinogenesis in vivo. “In that model, 
COX4-2 is downregulated from the earliest stages,” 
he said. “And, this makes sense because we have 
shown that COX4-2 makes cells more aerobic, 
which is the opposite of what the cancer wants. 
Therefore, our results suggest that the COX4-2 gene 
is a mechanism-based marker for lung cancer.”
Hüttemann’s current work aims to expand on 
these findings by investigating expression levels 
of COX4-2 with greater accuracy. He is developing 
probe ligation and rolling circle amplification 
techniques to detect levels of both COX4-1 and 
COX4-2. “Differences between the levels of these 
two genes may indicate the presence of cancer.”
The techniques entail Hüttemann’s lab 
synthesizing DNA segments, or “probes,” that 
recognize and attach to the target gene. Using DNA 
polymerase and a circular DNA template, DNA 
generation amplifies the target of the gene-specific 
probes 1000-fold.
“Using the DNA extensions, the signals of the 
two genes are ‘amplified,’ enabling our lab to locate 
and quantify the levels of COX4-1 and COX4-2 with 
much greater accuracy than we ever could before,” 
Hüttemann said. 
Hüttemann’s group is currently working to 
further develop the techniques into a robust 
working assay in the lab. Once this is achieved, the 
next step will be to test it using clinical specimens 
from lung cancer patients. 
Improved ability to measure the levels of the 
COX genes may result in a test for the early 
screening of lung cancer. “Only 15 percent of lung 
cancer tumors are detected in time to do something 
about it,” Hüttemann said. “Our hope with this 
assay is to develop a robust screening method. In 
particular, individuals at high risk for developing 
“In 70 percent of  all human 
diseases, we find a change in 
the oxygen environment, COX4-2 
levels may be one of  the early 
indicators of  that shift in lung 
cancer tissue.”
— Dr. Hüttemann
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Maik Hüttemann and his research team are 
developing a platform technology to screen 
for target genes in lung cancer and other 
diseases.  
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About Dr. Maik Hüttemann:         
Dr. Hüttemann received a B.S. and 
an M.S. in chemistry, and a Ph.D. in 
biochemistry and molecular biology 
from the University of Marburg in 
Germany. He joined Wayne State 
University in 2000. 
To learn more, visit: 
http://genetics.wayne.edu/faculty/huttemann/index.php
lung cancer, including smokers would benefit from 
such a test.”
Although lung cancer is Hüttemann’s primary 
interest, he also aims to develop the assay as a 
platform technology to screen for any gene. 
“Although this step is further into the future, 
if we can successfully develop the technology to 
detect a gene of interest and amplify its signal, our 
ability to screen for specific genes may increase 
dramatically,” Hüttemann said. “This, in turn, may 
help in the early detection of not only different 
kinds of cancers, but perhaps other diseases such 
as neurodegenerative disorders, diabetes and 
innumerable other health problems with a genetic 
footprint.”
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